Canadians support medical spending – is government listening?

Click on the graphic to access the report

BIOTECanada has just released the results of a poll conducted by Angus Reid which assessed public sentiment towards health and medical research.  The poll was conducted in December 2009 and includes the views of of 1,003 Canadians.

Looks like it’s time to step up our support for this innovative sector!

Some highlights from the report:

• 89% of Canadians say Canada should be a global leader in health research.

• Respondents said health care was the third most important issue facing Canada (12%) after the economy (32%) and the environment (13%).

• Canadians support spending 20 cents of every health care dollar on health and medical research (the actual spend is less than one cent).

• Within health care, the main issue is access to treatment and services.

• The allocation of resources should be 54.5% towards treatment and 45.5% towards prevention.

• Canadians would like to see higher priority given to science and technology stories in the media.

So there you have it: Canadians care deeply about the health care sector and strongly support government spending to advance our capabilities and services.

Related Blogs

 

Why the US mid-term elections matter to the Canadian pharma industry
Take the Pill, originally uploaded by messyatwork The upcoming US Congress and Senate mid-term elections will have far-reaching, unforeseen consequences, whatever the result may be. The President a

Dx2010: Markers to markets
What’s the future of genetic diagnostics? Where do the commercialization opportunities exist? Now we know. On June 22, the Ontario Genomics Institute and MaRS Future of MedicineTM jointly held

Will health care reform bankrupt America?
President Obama signed into law the Patient Protection and Affordable Care Act (ACA) on March 23, 2010. This landmark legislation marks the greatest change in the provision of health care in the US i

BioFinance ’11: Canadian biotech is back!
For several years, going to BioFinance was about as much fun as listening to a Leonard Cohen album. Now, however, we’re starting to see smiling faces.  We’re not out of the woods yet by

Clients wow at BioPartnering
Our life sciences and health care practice took three MaRS clients on the road to Vancouver last month to attend the 2011 BioPartnering North America (BPNA) meeting, the first major life sciences bus

Generic drugs are cheaper?
We’ve all heard multinational pharmaceutical companies claim that the cost of developing a single new drug is over $1.0 billion. Even though that cost includes all failed development efforts,Â

Tags: canada, health care, John McCulloch, policy